Financials in USD. Standardized financial statements.
A compact view of how Axsome Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $638.50M | $385.69M | $270.60M | $50.04M | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +65.5% | +42.5% | +440.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $47.48M | $33.30M | $26.07M | $5.20M | $0 | $0 | $37,330 | $48,935 | $42,557 | $20,484 |
| Gross Profit? | $591.02M | $352.39M | $244.53M | $44.84M | $0 | $0 | -$37,330 | -$48,935 | -$42,557 | -$20,484 |
| Gross Margin? | +92.6% | +91.4% | +90.4% | +89.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $760.25M | $632.95M | $476.36M | $224.64M | $124.71M | $99.14M | $67.11M | $32.85M | $27.16M | $27.54M |
| Operating Income? | -$169.24M | -$280.56M | -$231.82M | -$179.80M | -$124.71M | -$99.14M | -$67.25M | -$32.85M | -$27.16M | -$27.54M |
| EBITDA? | -$168.08M | -$272.60M | -$224.99M | -$175.40M | -$124.63M | -$100.31M | -$67.21M | -$32.58M | -$27.77M | -$27.52M |
| Income Before Tax | -$183.70M | -$287.13M | -$238.28M | -$187.13M | -$130.40M | -$102.90M | -$68.35M | -$30.97M | -$28.94M | -$27.20M |
| Income Tax Expense | -$530,000 | $85,000 | $960,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$183.17M | -$287.22M | -$239.24M | -$187.13M | -$130.40M | -$102.90M | -$68.35M | -$30.97M | -$28.94M | -$27.20M |
| EPS? | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 | $-2.83 | $-2.05 | $-1.15 | $-1.27 | $-1.42 |
| Diluted EPS? | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 | $-2.83 | $-2.05 | $-1.15 | $-1.27 | $-1.42 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality